HFpEF, but not HFrEF, is associated with reduced plasma nitric oxide metabolites, suggesting a mechanism for the benefits of inorganic nitrate supplementation.
HFpEF, but not HFrEF, is associated with reduced plasma NOM, suggesting greater endothelial dysfunction, enhanced clearance, or deficient dietary ingestion of inorganic nitrate. Our findings may underlie the salutary effects of inorganic nitrate supplementation demonstrated in recent clinical trials in HFpEF.
Chirinos et al. (2016) studied this question.